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Periodate-treated, non-anticoagulant heparin-carrying polystyrene consists of about ten periodate-oxidized, alkaline-degraded
low molecular weight-heparin chains linked to a polystyrene core and has a markedly lower anti-coagulant activity than
heparin. In this study, we evaluated the effect of non-anticoagulant heparin-carrying polystyrene on tumour growth and
metastasis. Non-anticoagulant heparin-carrying polystyrene has a higher activity to inhibit vascular endothelial growth factor-
165-, ﬁbroblast growth factor-2- or hepatocyte growth factor-induced human microvascular endothelial cell growth than
heparin, ten periodate-oxidized-heparin and ten periodate-oxidized-low molecular weight-heparin, which is probably due to
the heparin-clustering effect of non-anticoagulant heparin-carrying polystyrene. Non-anticoagulant heparin-carrying polystyrene
inhibited human microvascular endothelial cell, B16 melanoma and Lewis lung cancer cell adhesion to Matrigel-coated plates.
Non-anticoagulant heparin-carrying polystyrene also showed strong inhibitory activities in the tubular formation of endothelial
cells on Matrigel and B16-melanoma and Lewis lung cancer cell invasion in a Matrigel-coated chamber assay. In vivo studies
showed that growth of subcutaneous induced tumours and lung metastasis of B16-melanoma and Lewis lung cancer cells
were more effectively inhibited by non-anticoagulant heparin-carrying polystyrene than ten periodate-oxidized-heparin and ten
periodate-oxidized-low molecular weight-heparin. Furthermore, non-anticoagulant heparin-carrying polystyrene markedly
reduced the number of CD34-positive vessels in subcutaneous Lewis lung cancer tumours, indicating a strong inhibition of
angiogenesis. These results suggest that non-anticoagulant heparin-carrying polystyrene has an inhibitory activity on
angiogenesis and tumour invasion and may be very useful in cancer therapy.
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Heparin (Hep)/heparan sulphate (HS) are members of the glycosa-
minoglycans (GAGs) and are normally present as proteoglycans
(PGs), in which a number of Hep/HS-chains are covalently
attached to a core protein. While HS is widely distributed on cell
surfaces and in extracellular matrices in most animal tissues, Hep is
synthesised by mast cells in connective tissue and stored in cyto-
plasmic granules (Ishihara and Ono, 1998). Heparin is isolated
on a commercial basis from animal tissue (pig or bovine intestinal
mucosa, or bovine lung etc.) and has been extensively used as an
anti-thrombotic drug for a long time (Ishihara and Ono, 1998).
The biological role of Hep/HS is highly diverse. Aside from its
well-known anti-coagulant action, the molecules are found to be
associated with growth factors and cytokines in various biological
processes, as well as being involved in cell adhesion, recognition,
migration, and regulation of various enzymatic activities (Lindahl
et al, 1994; Kjellen and Lindahl, 1991).
Several studies have reported both inhibitory and stimulatory
effects of Hep on tumour growth and metastasis (Zacharski and
Ornstein, 1998; Engelberg, 1999; Smorenburg and Van Noorden,
2001). Besides the anticoagulant function, Hep binds to various
growth factors, cytokines, and extracellular matrix (ECM) proteins
and consequently is able to affect proliferation and migration of
cancer cells and angiogenesis in tumours (Lindahl et al, 1994).
Furthermore, Heps have been found to inhibit expression of onco-
genes and to affect the immune system (Smorenburg and Van
Noorden, 2001). Heparins also show both inhibitory and stimulatory
effects of various proteolytic enzymes, which are essential for inva-
sion of cancer cells and angiogenesis through the ECM (Zacharski
and Ornstein, 1998; Engelberg, 1999; Smorenburg and Van Noor-
den, 2001). Due to the wide variety of activities of Heps, the
ultimate effect of a Hep treatment on cancer progression is unpre-
dictable. In addition, the use of a high-dose Hep has been limited
by its strong anti-coagulant property, which may cause severe bleed-
ing complications (Levine et al, 1989; Lapierre et al, 1996).
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www.bjcancer.comPeriodate-treated, non-anticoagulant Hep-carrying polystyrene
(NAC-HCPS) has been described previously as a synthetic glyco-
conjugate that is soluble in water and has an amphiphilic structural
unit consisting of hydrophilic polysaccharides and hydrophobic
polystyrene moieties (Ishihara et al, 2000a). It has been estimated
that the molecular size of NAC-HCPS is approximately 80–
120 kDa and comprises of over ten periodate-oxidised, alkaline-
degraded low molecular weight (IO4-LMW-) Hep chains enriched
in trisulphated disaccharide structures linked to its polystyrene core
(Ishihara et al, 2000a,b). Non-anticoagulant Hep-carrying polystyr-
ene shows a signiﬁcantly reduced anticoagulant activity and
enhanced abilities to interact with various heparin-binding growth
factors, such as ﬁbroblast growth factor-2 (FGF-2), vascular
endothelial growth factor-165 (VEGF165) and hepatocyte growth
factor (HGF), which are known to stimulate angiogenesis (Ishihara
et al, 2000b).
The present study evaluates the effect of NAC-HCPS on malig-
nant processes in vitro and in vivo, thereby focusing on
angiogenesis. Non-anticoagulant Hep-carrying polystyrene inhibit,
(i) heparin-binding growth factor-induced human microvascular
endothelial cell (HMVEC) proliferation, (ii) HMVEC adhesion
onto Matrigel, (iii) formation of capillary-like tubular structures
on Matrigel by HMVECs in vitro, and (iv) vascularisation in
tumour tissue in vivo. In addition, NAC-HCPS is an inhibitor
for experimental subcutaneous tumour growth and metastasis to
the lung using B16 melanoma (B16) and Lewis lung cancer
(3LL) cells.
MATERIALS AND METHODS
Preparation of modiﬁed Heps and NAC-HCPS
Non-anticoagulant Hep-carrying polystyrene was prepared as has
been reported previously (Ishihara et al, 2000a). An outline of
the used chemical reaction route to synthesise modiﬁed heparins
and NAC-HCPS is presented in Figure 1. Brieﬂy, 25 g of Hep from
porcine intestine (185.8 USP Units mg
71) dissolved in 400 ml of
0.1 M NaIO4 in 0.05 M sodium acetate buffer (pH 5) was stirred
at 48C for 3 days. The unreacted NaIO4 was then neutralised by
addition of glycerol (25 ml), and the reaction mixture was subse-
quently dialysed and lyophilised. The product (non-reduced
periodate-oxidised heparin; non-reduced IO4-Hep) was then
degraded in an alkaline solution (pH 12) at room temperature
for 30 min, and the degraded product was recovered after dialysis
and lyophilisation as non-reduced periodate-oxidised, alkaline-
degraded (non-reduced IO4-LMW-) Hep. To prepare reduced
IO4-Hep and reduced IO4-LMW-Hep as control compounds in
order to compare with NAC-HCPS, both non-reduced IO4-Hep
and non-reduced IO4-LMW-Hep were reduced by mixing them
with 0.2 M sodium borohydride in 0.25 M sodium bicarbonate
for 3 h at 48C. The excess borohydride in both reactions was
destroyed by adding acetic acid (pH 5). The reduced IO4-Hep
and reduced IO4-LMW-Hep were then recovered after neutralising
with NaOH, dialysis and lyophilisation.
The non-reduced IO4-LMW-Hep (500 mg) and p-styrenemethy-
lamine (250 mg) were dissolved in 20 ml of 50 mM N,N,N',N'-
tetramethyl-ethylenediamine (pH 4.75), after which 1 ml of
0.8 mM NaCNBH3 was added. The reaction mixture was stirred
for 24 h at room temperature, dialysed and lyophilised to yield a
white powder (heparin-styrene monomer). This powder (100 mg)
and 2 mg of potassium peroxodisulphate were dissolved in 1 ml
of distilled water and the polymerisation was carried out at 608C
for 24 h under dried N2 gas. The reaction solution was then slowly
poured into an excess amount of ethanol to yield a polymeric
precipitate. Water-soluble impurities were separated from the
precipitate using ultra-ﬁltration and ﬁnally the NAC-HCPS was
obtained as a white powder after lyophilisation (Ishihara et al,
2000a). The weight fraction of NAC-Hep (non-reduced IO4-
LMW-Hep) component in the NAC-HCPS was estimated to be
92% using a carbazole assay (Ishihara et al, 2001).
Anti-coagulant activity
Blood plasma was drawn from a femoral artery of a male New
Zealand white rabbit (3 kg, Kitayama Labs Inc., Japan) anaesthe-
tised with an intramuscular injection containing xylazine (12 mg)
and ketamin (40 mg). The indicated concentration of native Hep,
IO4-Hep, IO4-LMW-Hep or NAC-HCPS was added to 10 ml of
plasma, and the activated partial thromboplastin time (APTT)
and prothrombin time (PT) were determined.
Cell culture
Lewis lung cancer cells (3LL) were obtained from the Cancer Cell
Repository (CCR) Institute of Development, Aging and Cancer
Tohoku University, Sendai, Japan. B16 melanoma cells (B16) were
obtained from the RIKEN Cell Bank, Saitama, Japan. These malig-
nant cells and ﬁbroblasts (human dermal ﬁbroblast, Takara
Biochemical Corp. Ohtsu, Japan) were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM, Life Technologies Oriental Inc., Tokyo,
Japan) supplemented with 10% heat-inactivated feotal bovine serum
(FBS), antibiotics (100 U ml
71 penicillin G and 100 mgm l
71 strep-
tomycin) under the atmosphere of 5% CO2 in air and 100% relative
humidity. Human microvascular endothelial cells (HMVEC, Takara
Biochemical Corp., Ohtsu, Japan) were grown in medium 199 (Life
Technologies Oriental Inc., Tokyo, Japan) supplemented with 10%
heat-inactivated FBS, antibiotics (100 U ml
71 penicillin G and
100 mgm l
71 streptomycin) and 10 ng ml
71 ﬁbroblast growth
factor-2 (FGF-2, R&D Systems, Minneapolis, MN, USA). The cells
used in this study were between the 4th and 8th passage.
Cell growth assay in vitro
Fibroblasts, 3LL and B16 cells (5610
3 per well) were seeded on 96-
well tissue culture plates (Falcon) in 100 ml of DMEM containing
the same FBS and antibiotics as mentioned above, as well as the
indicated concentration of either Hep, IO4-Hep, IO4-LMW-Hep
or NAC-HCPS, and grown for 3 days. Human microvascular
endothelial cells (5610
3 per well) were seeded on 96-well tissue
culture plates in 100 ml of medium 199, containing (i) the same
FBS and antibiotics as mentioned above, (ii) the indicated concen-
tration of either Hep, IO4-Hep, IO4-LMW-Hep or NAC-HCPS,
and (iii) one of the growth factors (either 4 ng ml
71 of VEGF165,
10 ng ml
71 of FGF-2 or 20 ng ml
71 of HGF), and grown for 5
days. After incubation, the depleted medium was replaced with
100 ml of fresh medium including 10 ml of WST-1 reagent (Cell
Counting Kit, Dojindo, Kumamoto, Japan) was added to each well,
and the optical density (OD) was read at 450 nm in an Immuno
Mini plate reader (Nunc InterMed Japan, Tokyo) after 1 h incuba-
tion at 378C. Results are expressed as percentage, using the mean
value of controls (without any heparinoid).
Cell adhesion onto Matrigel-coated plate
Human microvascular endothelial cells (1610
5 cells per well) were
plated on a Matrigel (20 ml of 0.5% DMEM solution per well,
Collaborative Biomedical Products, Two Oak Park, Bedford, MA,
USA) coated 24-well tissue culture plate in 1 ml of medium 199,
containing the same FBS, antibiotics and the indicated concentra-
tion of either Hep, IO4-Hep, IO4-LMW-Hep or NAC-HCPS
without 10 mg ml
71 FGF-2. Similarly B16 and 3LL cells
(1610
5 cells per well) were plated on the Matrigel-coated 24-well
tissue culture plate in DMEM, containing the same FBS, antibiotics
and the indicated concentration of either Hep, IO4-Hep, IO4-
LMW-Hep or NAC-HCPS. After 1 h incubation, the used medium
was removed and the Matrigel-coated wells were gently rinsed ﬁve
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British Journal of Cancer (2002) 86(11), 1803–1812 ã 2002 Cancer Research UKtimes with PBS to remove non-binding cells. The fresh medium
(450 ml) and 50 ml of WST-1 reagent (cell counting kit; Dojindo)
was added to each well, and the optical density (OD) of the
medium was measured at 450 nm in the Immuno Mini plate read-
er after 1 h incubation at 378C.
Tubular formation of HMVECs
Human microvascular endothelial cells (5610
4 cells per well) were
seeded on a Matrigel- (50 ml of 1% DMEM solution per well) coated
96-well tissue culture plate in 100 ml of medium 199, containing the
same FBS, antibiotics without 10 ng ml
71 FGF-2, and the indicated
concentration of either Hep, IO4-Hep, IO4-LMW-Hep or NAC-
HCPS as given above. After 8 h incubation, the formation of
tube-like structures by HMVEC was examined microscopically
and photographed at 6100 magniﬁcation. These micrographs were
scanned with a ﬁlm scanner and analysed using an image analyser
(NIH Image, Ver. 1.60, NIH, Bethesda. MD, USA). The total length
of a tube-like structure was expressed as percentage of the mean
value and related to control without any heparinoid.
Tumour cell invasion assay
The effect of NAC-HCPS on the invasion activity of tumour cells
was also evaluated using a growth factor-reduced Matrigel invasion
chamber (for a 24-well plate, 8 mm pore size, Becton Dickinson
Labware, Bedford, MA, USA) according to the method described
by Albini et al (1987) with some minor modiﬁcations. Brieﬂy, fresh
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Figure 1 Reaction scheme for the preparation of IO4-Hep, IO4-LMW-Hep and NAC-HCPS.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(11), 1803–1812media (DMEM, 0.75 ml) containing 0.1wt% BSA, 10wt% FBS as a
chemo-attractant, and the indicated concentration of either Hep,
IO4-Hep, IO4-LMW-Hep, or NAC-HCPS were added to the wells
of the plate (the lower chamber). The upper chamber had been
pre-coated with Matrigel by the manufacturer. Tumour (3LL or
B16) cells were suspended in DMEM containing 0.1% BSA and
the indicated concentration of either Hep, IO4-Hep, IO4-LMW-
Hep or NAC-HCPS at a cell density of 5610
4 cells ml
71, and
the cell suspensions (0.5 ml) were added into the upper chamber.
After 18 h incubation, non-invading cells were gently removed
from the upper surface of the membrane by wiping with a cotton
swab. The invaded cells to the lower side of the membrane were
stained with 0.4% Trypan blue solution and counted through
microscopic observation. Invasion rates were calculated according
to the following equation:
Invasion rate (%)=number of invading cells towards the lower
membrane side/number of invading cells towards the lower
membrane side without any heparinoid6100.
Tumour growth in vivo
Male C57BL/6 mice (6-7 weeks old) were purchased from Clea
Japan Inc., Tokyo, Japan. Tumour (3LL or B16) cells were trypsi-
nised and suspended in Hanks’ balanced salt solution (HBSS).
Tumour cells (1610
7) in 100 ml of HBSS were implanted into the
dorsal subcutis of the mice. After tumours had reached to a volume
of 100*200 mm
3 around 14 days (deﬁned as day 1), 200 mlo fI O 4-
Hep, IO4-LMW-Hep or NAC-HCPS (each 10 mg ml
71 of PBS
solution) was subcutaneously administered around the tumour daily
for another 6 days. Control mice were administered the same
volume of only PBS (200 ml per injection). The size of a tumour
on day 1 and day 8 was measured with calipers and tumour volume
was estimated as length6width6 height6p/6. The growth rate of a
tumour was then calculated as volume (day 8)/volume (day 1). The
3LL and B16 tumour volumes of control on day 8 were 3200+400
and 4300+500 mm
3, respectively. Each experimental group was
composed of eight mice. Data were compared with the mean
volume of the PBS treated group (represented as 100%).
Vascularity of the tumour
The NAC-HCPS-treated and control tumours of 3LL cells on day 8
were ﬁxed in 10% neutral buffered formaldehyde, and embedded
in parafﬁn for immuno-histochemical study. To evaluate the
microvessel density of the tumour, CD34 as an endothelial cell
(vessel) marker was stained by an indirect method (Tomisawa et
al, 1999; Oshika et al, 2000). After each section (4 mm thick) was
dehydrated and treated with 0.6% hydrogen peroxide in methanol
for 45 min, slides were autoclaved for antigen retrieval (1218C
15 min). Slides were then incubated with 5% normal goat serum
for 60 min and reacted with rat anti-murine CD34 monoclonal
antibody (1:20, Hycult Biotechnology, Uden, The Netherlands)
at 48C, overnight. Peroxidase-conjugated anti-rat IgG (1:200,
Amersham Life Science, Buckinghamshire, UK) was used as the
second antibody at room temperature for 60 min and the interac-
tions were visualised with 3,3'-diaminobenzidine-chromogen
(DAKO Japan, Kyoto). Finally, nuclear counterstaining was carried
out with Mayer’s haematoxylin. In each section, ﬁve randomised
areas (microscopic ﬁelds, 6100 magniﬁcant) that were considered
to show the largest vessel density, were photographed, and CD34-
stained vessels were counted. Each experimental group was
composed of six mice. Data have been compared with the average
value in PBS treated tumours, deﬁned as 100%.
Experimental metastasis
Mice were injected intravenously with 3610
5 cells of either 3LL or
B16 cells in 100 ml PBS through a lateral tail vein. From day 1 to
day 7, either IO4-Hep, IO4-LMW-Hep or HCPS (1 mg per 100 ml
PBS) or 100 ml of PBS only was administered intraveneously once a
day. All mice were sacriﬁced day 14 after the tumour cells were
injected, and the lungs of each mouse were removed. Lungs were
then ﬁxed in Bouin’s solution overnight and the surface tumour
nodules were counted under a stereoscopic microscope. The
numbers of 3LL and B16 tumour nodules in control (PBS-treated)
were 250+50 per mouse and 180+30 per mouse, respectively.
Each experimental group was composed of eight mice. Data were
evaluated against the mean values of the PBS treated group (repre-
sented as 100%).
Statistical analysis
All summarised data are expressed as the mean value+s.e.
Comparisons between means of multiple groups were analysed by
one-way analysis of variance and Scheffe’s multiple comparisons
test. All statistical analyses were carried out using the StatView
(version 5.0) statistical package (Abacus Concepts Inc., Berkeley,
CA, USA). All animal experiments have been carried out with ethi-
cal committee approval of the National Defense Medical College,
Tokorozawa, Saitama, Japan. The ethical guidelines that were
followed meet the standards required by Cancer Research UK
guidelines (Workman et al, 1998).
RESULTS
Anti-coagulant activity of NAC-HCPS
Addition of each Hep, IO4-Hep, IO4-LMW-Hep, and NAC-HCPS
prolonged the coagulation time of rabbit plasma in a dose-depen-
dent manner (Figure 2A, APTT). APTT of the rabbit plasma
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Figure 2 Anticoagulant activity of NAC-HCPS. APTT (A) and PT (B)o f
rabbit plasma containing various concentrations of NAC-HCPS, Hep, IO4-
Hep and IO4-LMW-Hep were measured, as has been described in Materi-
als and Methods.
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100 mgm l
71, Hep greatly prolonged APTT to about 800 s, while
IO4-Hep, IO4-LMW-Hep and NAC-HCPS prolonged APTT to
about 300, 160 and 160 s, respectively. As shown in Figure 2B,
the PT of rabbit plasma without any heparinoid is about 7 s. While
Hep strongly prolonged PT to about 27 s at the concentration of
100 mgm l
71,I O 4-Hep, IO4-LMW-Hep and NAC-HCPS only
prolonged the PT to 8 to 10 s. Since the periodate oxidation of
Hep is known to destruct a penta-saccharide structure which inter-
acts with antithrombin III (Conrad and Guo, 1991), the remainder
of the anticoagulant activities of IO4-Hep, IO4-LMW-Hep and
NAC-HCPS may result from interactions with other anticoagulant
factors, such as heparin co-factor II (Bourin and Lindahl, 1993).
Effect of NAC-HCPS on cell growth in vitro
Human microvascular endothelial cells were able to grow in
medium in the presence of 10% FBS without addition of a
speciﬁc growth factor. When VEGF165, FGF and HGF were
added to the culture medium, the growth rate of HMVEC
increased to 1.2–1.7-fold when compared to the control. Hori-
zontal lines in Figure 3A,B,C show the level of cell growth in
DMEM containing 10% FBS in the absence of exogenous growth
factors. While addition of low concentrations (below 8 mgm l
71)
of Hep, IO4-Hep or IO4-LMW-Hep to the medium did not
inﬂuence the growth of HMVEC in the presence of each growth
factor, high concentrations (more than 32 mgm l
71) slightly
inhibited the growth in a dose-dependent manner (Figure
3A,B,C). On the other hand, NAC-HCPS inhibited the growth
factor-induced HMVEC growth in a dose-dependent manner,
even at low concentrations (52 mgm l
71).
The doubling times of ﬁbroblast and 3LL cell growth in DMEM
containing 10% FBS and antibiotics were 25 and 17 h, respectively,
and the cell growth was not inﬂuenced upon addition of either
Hep, IO4-Hep, IO4-LMW-Hep or NAC-HCPS up to 500 mgm l
71
(Figure 4A,B). However, only NAC-HCPS inhibited B16 cell
growth in a dose-dependent manner (Figure 4C). The doubling
time of B16 cell growth in the control culture and 500 mgm l
71
NAC-HCPS containing culture were 18 and 23 h, respectively.
Effect of NAC-HCPS on tubular formation of HMVECs
Human microvascular endothelial cells are well known to form
capillary-like tubular structures when seeded on Matrigel (Collen
et al, 2000). The effect of NAC-HCPS in culture media on this
tubular formation of HMVEC was compared to that of Hep,
IO4-Hep and IO4-LMW-Hep. Figure 5A shows representative
microphotographs of tubular formation of HMVEC cultured in
the presence of respectively 2 or 32 mgm l
71 of NAC-HCPS,
Hep, IO4-Hep and IO4-LMW-Hep. While Hep, IO4-Hep, and
IO4-LMW-Hep showed a low inhibitory effect on the tubular
formation up to concentrations of 100 mgm l
71 (Figure 5B),
NAC-HCPS exhibited a strong inhibition on the tubular formation,
even at low concentration (2 mgm l
71, Figure 5A,B).
Effect of NAC-HCPS on tumour cell invasion
The inhibitory effect of NAC-HCPS on the migration and invasion
of tumour cells (3LL and B16) was examined using a Matrigel
invasion chamber (Albini et al, 1987). When 3LL and B16 cells
were cultured on the Matrigel invasion chamber without any
heparinoid, about 200 and 80 cells were invaded into the lower
side of the membrane, respectively. While both cell types showed
a slightly enhanced invasive activity in the presence of 4 mgm l
71
of Hep, IO4-Hep, and IO4-LMW-Hep, the invasive activities were
reduced in the presence of high concentrations (100 mgm l
71)o f
Hep, IO4-Hep, and IO4-LMW-Hep (Figure 6A,B). On the other
hand, the invasive activity of both cell types in the presence of
NAC-HCPS was strongly inhibited, even at a low concentration
(4 mgm l
71). Therefore, it is suggested that NAC-HCPS possesses
an anti-invasive activity for tumour cells.
Effect of NAC-HCPS on endothelial and tumour cell
adhesions to Matrigel-coated plates
The adhesions of HMVECs and tumour cells (3LL and B16) to
Matrigel-coated plates may be an important ﬁrst step in the tubular
formation of HMVECs on the Matrigel, as well as tumour cell
invasion through the Matrigel invasion chamber, respectively. We
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Figure 3 Effect of NAC-HCPS on growth factor-stimulated HMVEC
growth. (A) VEGF165,( B) FGF-2, (C) HGF. Cell growth incubated with
a growth factor in the absence of heparinoid was deﬁned as 100% growth,
and the data were calculated as a percentage. The horizontal line in each
panel represents the level of cell growth obtained in the absence of both
growth factor and heparinoid. The results represent the mean+s.e. in tri-
plicate.
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cell adhesion to Matrigel-coated plates. All HMVEC, 3LL and B16
cells adhered to the Matrigel-coated plates within 1 h in the
absence of NAC-HCPS (Figure 7) showing spreading shapes on
the surface. On the other hand, NAC-HCPS inhibited adhesion
of all the HMVEC, 3LL and B16 cells to the Matrigel-coated plates
in a concentration-dependent manner (Figure 7). Furthermore,
almost all cells of these three cell types retained their spherical
shapes in the presence of high concentrations of NAC-HCPS (20
and 100 mgm l
71) up to 5 h (data not shown). However, neither
Hep, IO4-Hep nor IO4-LMW-Hep showed the cell shape-retaining
effect.
Effect of NAC-HCPS on tumour growth in vivo
A measurable tumour (tumour volume: 100*200 mm
3) was
formed 14 days after implantation of tumour cells (3LL or B16).
As shown in Figure 8A, IO4-Hep and IO4-LMW-Hep reduced
subcutaneous induced tumour growth of 3LL cells to various
extents. NAC-HCPS more strongly inhibited tumour growth to
about 40% of the PBS treated group (P= 0.0065, vs PBS) than
IO4-Hep and IO4-LMW-Hep. On the other hand, while IO4-Hep
and IO4-LMW-Hep did not signiﬁcantly reduce the subcutaneous
induced tumour growth of B16 melanoma (Figure 8B), NAC-
HCPS signiﬁcantly inhibited the tumour growth to about 10% of
the PBS treated group (P50.0001, vs PBS).
Effect of NAC-HCPS on vascularity of the tumour in vivo
To evaluate the effect of NAC-HCPS on anti-angiogenesis, immu-
no-histochemical staining of murine CD34 of NAC-HCPS treated
and control tumours of 3LL cells were carried out (Tomisawa et
al, 1999; Oshika et al, 2000). Representative microphotographs of
CD34 immuno-localisation in controls (PBS-treated) and NAC-
HCPS treated subcutaneous induced tumours are shown in Figure
9A,B. In PBS treated mice, many CD34 positive stained vessels
were diffusely located and clearly formed tube-like structures in
the tumour. On the other hand, CD34 positive stained vessels were
nearly absent in the NAC-HCPS treated tumours and tube-like
structures were not observed. As shown in Figure 9C, NAC-HCPS
signiﬁcantly reduced the number of CD34 positive vessels
(P=0.0031), suggesting that NAC-HCPS signiﬁcantly inhibited
angiogenesis in tumours.
Effect of NAC-HCPS on experimental metastasis
To evaluate the inhibitory effect of NAC-HCPS on lung colony
formation of tumour cells (3LL or B16), IO4-LMW-Hep, IO4-
Hep and NAC-HCPS (each 1 mg per 100 ml PBS) was intrave-
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71 of NAC-HCPS, Hep, IO4-Hep
and IO4-LMW-Hep for 8 h on Matrigel-coated plates. Results are repre-
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of NAC-HCPS, Hep, IO4-Hep and IO4-LMW-Hep.
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Therefore, Hep was excluded in this study. As shown in Figure
10A, IO4-LMW-Hep, IO4-Hep and NAC-HCPS inhibited lung
colonisation of 3LL cells. Similarly in Figure 10B, all IO4-LMW-
Hep, IO4-Hep and NAC-HCPS also showed lung colonisation inhi-
bition of B16 cells. Furthermore, in IO4-LMW-Hep, IO4-Hep and
PBS treated mice, a number of 3–20 tumour colonies of 3LL or
B16 cells in liver were always observed in each mouse, while in
NAC-HCPS treated mice, no colony formation of tumour cells
in liver was observed (data not shown). Thus, NAC-Heps, espe-
cially NAC-HCPS, possess signiﬁcant anti-metastasis activity of
3LL and B16 cells.
DISCUSSION
Heparin is clinically used as an antithrombotic agent, but its high
dose use has been limited by its strong intrinsic anti-coagulant
property itself, causing severe bleeding complications (Levine et
al, 1989). If Hep could be modiﬁed to minimise its anti-coagulant
property and to enhance its activities to inhibit tumour growth and
metastasis, then such a modiﬁed Hep would be a very useful drug
in treating malignant diseases. Periodate-oxidised (IO4-) Hep and
periodate-oxidised, alkaline-degraded low molecular weight (IO4-
LMW-) Hep (Fransson and Carlstedt, 1974; Fransson, 1978) are
known for not having a speciﬁc pentasaccharide structure to inter-
act with antithrombin III (Conrad and Guo, 1991), and therefore
its anti-coagulant activity (APTT and PT) is much lower than
Hep (Figure 2). We previously reported the preparation of NAC-
HCPS using the IO4-LMW-Hep (Ishihara et al, 2000a). In this
study, we have demonstrated that NAC-HCPS inhibits subcuta-
neously induced tumour growth and metastasis to lung of B16
melanoma and 3LL (Lewis lung cancer) cell line.
In the present study, NAC-HCPS when compared to Hep, IO4-
Hep and IO4-LMW-Hep, has strong anti-angiogenic properties.
This inhibitory effect of NAC-HCPS can not be ascribed to cyto-
toxicity, since it has been found that NAC-HCPS in
concentrations up to 500 mgm l
71 do not inhibit the HMVEC
growth in the absence of those growth factors (data not shown).
NAC-HCPS inhibited the adhesion of HMVECs and tumour cells
to the Matrigel-coated plate, as well as the tubular formation of
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ably due to inhibition of the cell adhesion to the Matrigel as well as
inhibition of heparin-binding growth factors. Moreover, endothe-
lial cells in the extracellular matrix need binding to adhesive
proteins to initiate invasion and migration (McCathy et al,
1990). Heparins, especially NAC-HCPS, can effectively bind to
various adhesive proteins such as ﬁbronectin, laminin and collagen,
and thus may affect cell adhesion and tubular formation. Finally,
NAC-HCPS markedly reduced the number of CD34-positive
vessels (a marker of microvascular endothelial cells) in subcuta-
neous 3LL tumours (Tomisawa et al, 1999; Oshika et al, 2000).
The above results demonstrate that NAC-HCPS with its reduced
anticoagulant property has a strong anti-angiogenesis. This anti-
angiogenesis activity may be the explanation for the observed in
vivo inhibition of experimental subcutaneous tumour growth.
In this study, it has been demonstrated that NAC-HCPS inhibits
the adhesion of tumour cells to Matrigel-coated plates, probably
due to the Hep-clustering effect of NAC-HCPS (Figure 7). In addi-
tion, immobilization of Hep onto Matrigel was important for the
inhibitory effect of NAC-HCPS on tumour cell adhesion to Matri-
gel. As we reported previously, NAC-HCPS is effectively adsorbed
to various polymeric surfaces (Ishihara et al, 2000a), collagen (type
I)-substratum (Ishihara et al, 2001) and Matrigel (data not shown)
through a hydrophobic interaction between the hydrophobic
surface and polystyrene core of NAC-HCPS. And cell adhesion of
tumour cells (B16 and 3LL) were similarly inhibited by immobili-
sation of NAC-HCPS on the Matrigel (data not shown).
Invasive properties are characteristic of malignant cells, and
essential to tumour growth. Tumour cells use speciﬁc enzymes to
solubilise extracellular matrix during tumour invasion. This degra-
dation of the extracellular matrix takes place at highly localised
regions in close vicinity to the cancer, where active proteolytic
enzymes outbalance natural protease inhibitors present in the
extracellular environment (Basbaum and Werb, 1996). These
proteases are produced by either inﬂammatory cells, stromal cells
or the tumour cell themselves (Liotta, 1992). Heparin, chemically
modiﬁed heparins and related sulphated polysaccharides are known
to be effective inhibitors for heparanase (Irimura et al, 1986;
Vlodavsky et al, 1994; Lapierre et al, 1996) and various matrix
metalloproteases (MMPs) including MMP-1, -2, -3 and -9 (Kenagy
et al, 1994; Gogly et al, 1998). MMP-2 and -9 are suggested to play
a major role in metastasis (Kugler, 1999; Westermarck and Kahari,
1999). Heparanase activity has also been found to correlate with
the metastatic potential of various types of cancer cells (Nakajima
et al, 1988). In this study the dose-dependent inhibition of NAC-
HCPS on the invasion of tumour cells into Matrigel has been
observed (Figure 6). It is possible that an enhanced inhibition of
active proteolytic enzymes, as well as inhibition of adhesion of
tumour cells to Matrigel by NAC-HCPS result in the strong inhibi-
tion of the tumour cell invasions. Tumour cell adhesion to sub-
endothelial matrix and the subsequent invasion into the matrix
are common pathways for tumour cells to escape from blood ﬂow.
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caused through the inhibition of adhesion and invasion of tumour
cells (B16 and 3LL).
Our additional studies also have revealed that IO4-LMW-Hep
and NAC-HCPS have about a 10-fold smaller anticoagulant activity
(APTT) than native Hep. The residual anticoagulant activity of
NAC-HCPS is probably mediated by interaction with heparin co-
factor II, and not antithrombin III (Conrad and Guo, 1991;
Lapierre et al, 1996). In many tumour types, ﬁbrin is a major
component of the initial stroma (Costantini and Zacharski,
1992). Fibrin provides a scaffold for both invasive cancer and
endothelial cells, thereby contributing to tumour growth and
neo-vascularisation (Dvorak et al, 1987). The structure and
mechanical properties of the ﬁbrin matrix play a regulating role
in the formation of capillary-like tubular structures (Nehls and
Herrmann, 1996). Hep with its anticoagulant activity is thus
expected to inhibit the formation of ﬁbrin and microthrombi.
Whether the low anticoagulant activity of NAC-HCPS contributes
to its anti-tumour and anti-angiogenesis properties remains to be
determined.
Compared with sulphated polysaccharides like Hep, NAC-HCPS
has the advantage of exhibiting less toxicity due to its reduced anti-
coagulant activity. The subcutaneous haemorrhages were never
observed in mice injected with the same amount of NAC-HCPS,
and the NAC-HCPS treated mice lived longer. Furthermore, when
1 mg of NAC-HCPS was intravenously injected daily for 7 conse-
cutive days, only minor increases for the values of GOT (glutamic-
oxaloacetic transaminase), GPT (glutamic-pyruvic transaminase),
BUN (blood urea nitrogen), and Crea (creatinine) were observed,
returning to normal values within 7 days after the ﬁnal injection
(data not shown). However, sufﬁcient data are not yet available
of the complete toxicity proﬁle of NAC-HCPS, and standard toxi-
cologic and metabolic studies should be carried out in more detail
to conﬁrm the clinical safety of NAC-HCPS.
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Figure 10 Effect of NAC-HCPS on lung colonisation of 3LL cells (A)
and B16 cells (B) in mice. Both tumour cells (3610
5) were intraveneously
injected through the lateral tail vein. From day 1 to day 7, either NAC-
HCPS, IO4-Hep, IO4-LMW-Hep (1 mg per 100 ml of PBS) or 100 mlo f
PBS only was daily administered intraveneously through the lateral tail vein,
and colony numbers on the lung surface in each mouse were counted on
day 14.
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